Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Autografting

Tandem autologous-allo-SCT is feasible in patients with high-risk relapsed non-Hodgkin’s lymphoma

Bone Marrow Transplantation volume 48, pages 249–252 (2013)Cite this article

Subjects

Abstract

Allo-SCT is used to exploit GVL effect in high-risk relapsed non-Hodgkin’s lymphoma (NHL). Here, we retrospectively analyzed 34 high-risk NHL patients who underwent auto-SCT followed closely by reduced-intensity allo-SCT (‘tandem auto–allo’) from January 2002 to November 2010. The search for an allogeneic donor was started at the beginning of salvage regimen. Median patients’ age was 47 (27–68) years; histotypes were: diffuse large B-cell n=5, follicular n=14, transformed follicular n=4, mantle-cell n=5, plasmocytoid lymphoma n=1, anaplastic large T-cell n=2, peripheral T-cell n=3. Donors were HLA-identical siblings (n=29) or 10/10-matched unrelated individuals (n=5). Median interval between auto-SCT and allo-SCT was 77 days (36–197). At a median follow-up of 46 (8–108) months since allo-SCT, 5-year OS is 77% (61–93) and PFS is 68% (51–85). Disease relapse or progression occurred in six patients, 100-day TRM was 0%, 2-year TRM incidence was 6%. In conclusion, tandem transplantation is feasible in high-risk NHL patients having a HLA-identical donor. This approach could represent a suitable therapeutic option for those patients with high-risk NHL potentially benefitting from further therapy after auto-SCT. Donor searches should be started promptly whenever such an approach is chosen.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med 1995; 7: 1540–1545.

    Article  Google Scholar 

  2. Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 2010; 28: 4184–4190.

    Article  Google Scholar 

  3. Corradini P, Dodero A, Farina L, Fanin R, Patriarca F, Miceli R et al. Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome. Leukemia 2007; 21: 2316–2323.

    Article  CAS  Google Scholar 

  4. Thomson KJ, Morris EC, Bloor A, Cook G, Milligan D, Parker A et al. Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma. J Clin Oncol 2009; 27: 426–432.

    Article  Google Scholar 

  5. Sirvent A, Dhedin N, Michallet M, Mounier N, Faucher C, Yakoub-Agha I et al. Low nonrelapse mortality and prolonged long-term survival after reduced-intensity allogeneic stem cell transplantation for relapsed or refractory diffuse large B cell lymphoma: report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire. Biol Blood Marrow Transplant 2010; 16: 78–85.

    Article  Google Scholar 

  6. Khouri IF, McLaughlin P, Saliba RM, Hosing C, Korbling M, Lee MS et al. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood 2008; 111: 5530–5536.

    Article  CAS  Google Scholar 

  7. Freytes CO, Loberiza FR, Rizzo JD, Bashey A, Bredeson CN, Cairo MS et al. Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: a report of the International Bone Marrow Transplant Registry. Blood 2004; 104: 3797–3803.

    Article  CAS  Google Scholar 

  8. van Besien K, Carreras J, Bierman PJ, Logan BR, Molina A, King R et al. Unrelated donor hematopoietic cell transplantation for non-hodgkin lymphoma: long-term outcomes. Biol Blood Marrow Transplant 2009; 15: 554–563.

    Article  Google Scholar 

  9. Philip T, Armitage JO, Spitzer G, Chauvin F, Jagannath S, Cahn JY et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med 1987; 316: 1493–1498.

    Article  CAS  Google Scholar 

  10. Guglielmi C, Gomez F, Philip T, Hagenbeek A, Martelli M, Sebban C et al. Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial. J Clin Oncol 1998; 16: 3264–3269.

    Article  CAS  Google Scholar 

  11. Hamlin PA, Zelenetz AD, Kewalramani T, Qin J, Satagopan JM, Verbel D et al. Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2003; 102: 1989–1996.

    Article  CAS  Google Scholar 

  12. Blaise D, Farnault L, Faucher C, Marchetti N, Fürst S, El Cheikh J et al. Reduced-intensity conditioning with Fludarabin, oral Busulfan, and thymoglobulin allows long-term disease control and low transplant-related mortality in patients with hematological malignancies. Exp Hematol 2010; 38: 1241–1250.

    Article  CAS  Google Scholar 

  13. Crocchiolo R, Fürst S, Esterni B, Castagna L, El-Cheikh J, Faucher C et al. Two days of ATG in the conditioning regimen is associated with a reduced incidence of both acute and chronic GvHD without increasing relapse in RIC transplant for haematological disease. Bone Marrow Transplant 2011; 46 (Suppl 1s, abstract 288).

  14. Kaplan EL, Meier P . Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481.

    Article  Google Scholar 

  15. Gooley TA, Leisenring W, Crowley J, Storer BE . Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999; 18: 695–706.

    Article  CAS  Google Scholar 

  16. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295–304.

    Article  CAS  Google Scholar 

  17. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204–217.

    Article  CAS  Google Scholar 

  18. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945–956.

    Article  Google Scholar 

  19. Cox DR . Regression models and life tables. J Royal Stat Soc 1972; 34: 187–220.

    Google Scholar 

  20. Carella AM, Cavaliere M, Lerma E, Ferrara R, Tedeschi L, Romanelli A et al. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma. J Clin Oncol 2000; 18: 3918–3924.

    Article  CAS  Google Scholar 

  21. Gutman JA, Bearman SI, Nieto Y, Sweetenham JW, Jones RB, Shpall EJ et al. Autologous transplantation followed closely by reduced-intensity allogeneic transplantation as consolidative immunotherapy in advanced lymphoma patients: a feasibility study. Bone Marrow Transplant 2005; 36: 443–451.

    Article  CAS  Google Scholar 

  22. Buser AS, Heim D, Bucher C, Tichelli A, Gratwohl A, Passweg JR . High-dose chemotherapy using BEAM for tumor debulking without stem cell support followed by early allogeneic reduced intensity conditioning transplantation to induce a graft-versus-lymphoma effect in patients with high risk or refractory lymphoma. Bone Marrow Transplant 2004; 33: 1011–1014.

    Article  CAS  Google Scholar 

  23. Buser AS, Stern M, Bucher C, Arber C, Heim D, Halter J et al. High-dose chemotherapy using BEAM without autologous rescue followed by reduced-intensity conditioning allogeneic stem-cell transplantation for refractory or relapsing lymphomas: a comparison of delayed versus immediate transplantation. Bone Marrow Transplant 2007; 39: 335–340.

    Article  CAS  Google Scholar 

  24. Cohen S, Kiss T, Lachance S, Roy DC, Sauvageau G, Busque L et al. Tandem autologous-allogeneic nonmyeloablative sibling transplantation in relapsed follicular lymphoma leads to impressive progression-free survival with minimal toxicity. Biol Blood Marrow Transplant 2011 (e-pub ahead of print 7 December 2011).

  25. Tiercy JM, Nicoloso G, Passweg J, Schanz U, Seger R, Chalandon Y et al. The probability of identifying a 10/10 HLA allele-matched unrelated donor is highly predictable. Bone Marrow Transplant 2007; 40: 515–522.

    Article  CAS  Google Scholar 

  26. Tiercy JM, Bujan-Lose M, Chapuis B, Gratwohl A, Gmür J, Seger R et al. Bone marrow transplantation with unrelated donors: what is the probability of identifying an HLA-A/B/Cw/DRB1/B3/B5/DQB1-matched donor? Bone Marrow Transplant 2000; 26: 437–441.

    Article  CAS  Google Scholar 

  27. Rodrigues CA, Sanz G, Brunstein CG, Sanz J, Wagner JE, Renaud M et al. Analysis of risk factors for outcomes after unrelated cord blood transplantation in adults with lymphoid malignancies: a study by the Eurocord-Netcord and lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol 2009; 27: 256–263.

    Article  Google Scholar 

  28. Wang HX, Yan HM, Liu J, Duan LN, Wang ZD, Zhu L et al. Haploidentical hematopoietic stem-cell transplantation for non-Hodgkin lymphoma with bone marrow involvement. Leuk Lymphoma 2009; 50: 1488–1493.

    Article  CAS  Google Scholar 

  29. Dodero A, Carniti C, Raganato A, Vendramin A, Farina L, Spina F et al. Haploidentical stem cell transplantation after a reduced-intensity conditioning regimen for the treatment of advanced hematologic malignancies: posttransplantation CD8-depleted donor lymphocyte infusions contribute to improve T-cell recovery. Blood 2009; 113: 4771–4779.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank all personnel working at Hematology Department and Cellular Therapy Unit at Institut Paoli-Calmettes and at Hematology Department at Istituto Humanitas for their remarkable contribution in patients’ care and assistance to their families.

Author information

Authors and Affiliations

  1. Département d'Hématologie, Programme de Transplantation et de Thérapie Cellulaire, Institut Paoli-Calmettes, Marseille, France

    R Crocchiolo, L Castagna, S Fürst, J El-Cheikh, C Faucher, C Oudin, A Granata, R Bouabdallah, D Coso, C Chabannon & D Blaise

  2. Dipartimento di Oncoematologia, Istituto Clinico Humanitas, Milano, Italy

    L Castagna, M Balzarotti & A Santoro

  3. Inserm, CBT-510, Marseille, France

    C Chabannon & D Blaise

  4. Aix-Marseille University, Université d’Aix-Marseille, Marseille, France

    C Chabannon

Authors
  1. R Crocchiolo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L Castagna
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S Fürst
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J El-Cheikh
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C Faucher
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C Oudin
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A Granata
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. R Bouabdallah
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. D Coso
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. C Chabannon
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. M Balzarotti
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. A Santoro
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. D Blaise
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R Crocchiolo.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Crocchiolo, R., Castagna, L., Fürst, S. et al. Tandem autologous-allo-SCT is feasible in patients with high-risk relapsed non-Hodgkin’s lymphoma. Bone Marrow Transplant 48, 249–252 (2013). https://doi.org/10.1038/bmt.2012.116

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2012.116

Keywords

This article is cited by

Search

Advanced search

Quick links